Experimental Hematology
Volume 36, Issue 7 , Pages 773-785 , July 2008

Alternative treatment paradigm for thalassemia using iron chelators

  • Natasha Szuber

      Affiliations

    • Departments of Physiology, Medicine, and Experimental Medicine, McGill University, Montreal, Quebec, Canada
    • Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Joan L. Buss

      Affiliations

    • Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • ,
  • Shan Soe-Lin

      Affiliations

    • Departments of Physiology, Medicine, and Experimental Medicine, McGill University, Montreal, Quebec, Canada
    • Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Hady Felfly

      Affiliations

    • Department of Molecular Genetics and Development, Institut de Recherches Cliniques de Montreal, Quebec, Canada
    • ,
  • Marie Trudel

      Affiliations

    • Department of Molecular Genetics and Development, Institut de Recherches Cliniques de Montreal, Quebec, Canada
    • Department of Medicine, Université de Montreal, Quebec, Canada
    • Drs. Trudel and Ponka contributed equally to this work as co-senior authors.
    • ,
  • Prem Ponka

      Affiliations

    • Departments of Physiology, Medicine, and Experimental Medicine, McGill University, Montreal, Quebec, Canada
    • Lady Davis Institute for Medical Research, Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada
    • Corresponding Author InformationOffprint requests to: Prem Ponka, M.D., Ph.D., Lady Davis Institute for Medical Research, 3755 Cote Ste-Catherine Road, Montreal, Quebec, Canada, H3T 1E2
    • Drs. Trudel and Ponka contributed equally to this work as co-senior authors.

Received 27 June 2007 ,Revised 16 January 2008 ,Accepted 23 January 2008.

References 

  1. Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G. Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Ann N Y Acad Sci. 2005;1054:196–205
  2. Hebbel RP. The sickle erythrocyte in double jeopardy: autoxidation and iron decompartmentalization. Semin Hematol. 1990;27:51–69
  3. Weatherall DJ. Pathophysiology of thalassemia. Baillière's Clin Haematol. 1998;11:127–146
  4. Rund D, Rachmilewitz EA. Pathophysiology of α- and β-thalassemia: therapeutic implications. Semin Hematol. 2001;38:343–349
  5. Testa U, Hinard N, Beuzard Y, et al. Excess α chains are lost from β-thalassemic reticulocytes by proteolysis. J Lab Clin Med. 1981;98:352–363
  6. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet. 1998;10:1655–1658
  7. Weiss MJ, Zhou S, Feng L, et al. Role of alpha-hemoglobin stabilizing protein in normal erythropoiesis and beta-thalassemia. Ann N Y Acad Sci. 2005;1054:103–117
  8. Wainscoat JS, Kanavakis E, Wood WG, et al. Thalassaemia intermedia in Cyprus: the interaction of alpha and beta thalassaemia. Br J Haematol. 1983;53:411–416
  9. Rachmilewitz EA. Denaturation of the normal and abnormal hemoglobin molecule. Semin Hematol. 1974;11:441–462
  10. Repka T, Shalev O, Reddy R, et al. Nonrandom association of free iron with membranes of sickle and beta-thalassemic erythrocytes. Blood. 1993;82:3204–3210
  11. Grinberg LN, Rachmilewitz EA, Kitrossky N, Chevion M. Hydroxyl radical generation in beta-thalassemic red blood cells. Free Radic Biol Med. 1995;18:611–615
  12. Schrier SL. Pathophysiology of thalassemia. Curr Opin Hematol. 2002;9:123–126
  13. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood. 1988;71:1124–1129
  14. Vecchio C, Derchi G. Management of cardiac complications in patients with thalassemia major. Semin Hematol. 1995;32:288–296
  15. Wonke B. Clinical management of β-thalassemia major. Semin Hematol. 2001;38:350–359
  16. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3452–3455
  17. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol. 1995;32:304–312
  18. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051–2052
  19. Shalev O, Repka T, Goldfarb A, et al. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood. 1995;86:2008–2013
  20. Browne PV, Shalev O, Kuypers FA, et al. Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. J Clin Invest. 1997;100:1459–1464
  21. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339:417–422
  22. De Franceschi L, Shalev O, Piga A, et al. Deferiprone therapy in homozygous human β-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. J Lab Clin Med. 1999;133:64–69
  23. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica. 2000;85:115–117
  24. Richardson DR. The controversial role of deferiprone in the treatment of thalassemia. J Lab Clin Med. 2001;137:324–329
  25. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583–1587
  26. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332):516–520
  27. Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107:3436–3441
  28. Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf. 2007;6:235–239
  29. Ponka P, Borova J, Neuwirt J, Fuchs O. Mobilization of iron from reticulocytes: identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. 1979;97:317–321
  30. Baker E, Vitolo ML, Webb J. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol. 1985;34:3011–3017
  31. Ponka P, Richardson DR, Baker E, Schulman HM, Edward JT. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta. 1988;967:122–129
  32. Baker E, Richardson DR, Gross S, Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology. 1992;15:492–501
  33. Buss JL, Hermes-Lima M, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogues. Adv Exp Med Biol. 2002;509:205–229
  34. Buss JL, Arduini E, Ponka P. Mobilization of intracellular iron by analogs of pyridoxal isonicotinoyl hydrazone (PIH) is determined by the membrane permeability of the iron-chelator complexes. Biochem Pharmacol. 2002;61:1689–1701
  35. Buss JL, Arduini E, Shephard KC, Ponka P. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells. Biochem Pharmacol. 2003;65:349–360
  36. Cikrt M, Ponka P, Necas E, Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol. 1980;45:275–283
  37. Blaha K, Cikrt M, Nerudova J, Fornuskova H, Ponka P. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood. 1998;91:4368–4372
  38. Scott MD, Rouyer-Fessard P, Lubin BH, Beuzard Y. Entrapment of purified alpha-hemoglobin chains in normal erythrocytes: a model for β-thalassemia. J Biol Chem. 1990;265:17953–17959
  39. Scott MD, van den Berg JJ, Repka T, et al. Effect of excess α-hemoglobin chains on cellular and membrane oxidation in model β-thalassemic erythrocytes. J Clin Invest. 1993;91:1706–1712
  40. Ciavatta DJ, Ryan TM, Farmer SC, Townes TM. Mouse model of human β0 thalassemia: Targeted deletion of the mouse βmaj- and β min-globin genes in embryonic stem cells. Proc Natl Acad Sci. 1995;92:9259–9263
  41. Beauchemin H, Blouin M-J, Trudel M. Differential regulatory and compensatory responses in hematopoiesis/erythropoiesis in α- and β-globin hemizygous mice. J Biol Chem. 2004;279:19471–19480
  42. Bucci E, Fronticelli C. A new method for the preparation of α- and β-subunits of human hemoglobin. J Biol Chem. 1965;240:551–552
  43. Turci SM, McDonald MJ. Isolation of normal and variant hemoglobin chains. J Chromatogr. 1985;343:168–174
  44. Scott MD, Eaton JW, Kuypers FA, Chiu DT-Y, Lubin BH. Enhancement of erythrocyte superoxide dismutase activity: effects on cellular oxidant defense. Blood. 1989;74:2542–2549
  45. Scott MD, Kuypers FA, Butikofer P, Bookchin RM, Ortiz O, Lubin BH. Effect of osmotic lysis-resealing on red cell structure and function. J Lab Clin Med. 1990;115:470–480
  46. Dodge JT, Mitchell C, Hanahan DJ. The preparation and characteristics of hemoglobin-free ghosts of human erythrocytes. Arch Biochem Biophys. 1963;100:119–130
  47. Kuross SA, Rank BH, Hebbel RP. Excess heme in sickle erythrocyte inside-out membranes: possible role in thiol oxidation. Blood. 1988;71:876–882
  48. Edward JT, Gauthier M, Chubb FL, Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data. 1988;33:538–540
  49. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278–297
  50. Huang AR, Ponka P. A study of the mechanism of action of pyridoxal isonicotinoyl hydrazone at the cellular level using reticulocytes loaded with non-heme 59Fe. Biochim Biophys Acta. 1983;757:306–315
  51. Morgan EH. Chelator-mediated iron efflux from reticulocytes. Biochim Biophys Acta. 1983;733:39–50
  52. Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta. 2001;1536:133–140
  53. Beddington RS, Robertson EJ. An assessment of the developmental potential of embryonic stem cells in the midgestation mouse embryo. Development. 1989;105:733–737
  54. Alzet Mini-Osmotic Pump Model 2001 Instruction and Specification Sheet, Alzet Technical Information Services. Cupertino, CA: DURECT Corporation.
  55. Beutler EA, Hoffbrand V, Cook JD. Iron deficiency and overload. In: The American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology; 2003;p. 40–61
  56. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration. Semin Hematol. 1990;27:112–116
  57. Tricta F, Spino M. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med. 1998;339:1710
  58. Hershko C, Avramovici-Grisaru S, Link G, Gelfland L, Sarel S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med. 1981;98:99–108
  59. Johnson DK, Pippard MJ, Murphy TB, Rose NJ. An in vivo evaluation of iron chelating drugs derived from pyridoxal and its analogs. J Pharmacol Exp Ther. 1982;221:399–403
  60. Sterba M, Simunek T, Mazurova Y, et al. Safety and tolerability of repeated administration of pyridoxal 2-chlorobenzoyl hydrazone in rabbits. Hum Exp Toxicol. 2005;24:581–589
  61. Sterba M, Popelova O, Simunek T, et al. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity. J Pharmacol Exp Ther. 2006;319:1336–1347
  62. Kuross SA, Hebbel RP. Nonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation. Blood. 1988;72:1278–1285
  63. Szebeni J, Winterbourn CC, Carrell RW. Oxidative interactions between haemoglobin and membrane lipid: a liposome model. Biochem J. 1984;220:685–692
  64. Winterbourn CC. Reactions of superoxide with hemoglobin. In:  Greenwald RA editors. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton, FL: CRC Press; 1986;p. 137–141
  65. Hoffmann-Fezer G, Maschke H, Zeitler HJ, et al. Direct in vivo biotinylation of erythrocytes as an assay for red cell survival studies. Ann Hematol. 1991;63:214–217
  66. Pountney DJ, Konijn AM, McKie AT, Peters TJ, Raja KB. Iron proteins of duodenal enterocytes isolated from mice with genetically and experimentally altered iron metabolism. Br J Haematol. 1999;105:1066–1073
  67. Ferreira C, Santambrogio P, Martin M-E, et al. H ferritin knockout mice: a model of hyperferritinemia in the absence of iron overload. Blood. 2001;98:525–532
  68. Ansell J, Micklem H. Genetic markers for following cell populations. In:  Weir DM,  Herzenberg LA,  Blackwell CC editor. Handbook of Experimental Immunology. 4th ed.. Edinburgh, Scotland: Blackwell Publishers; 1986;p. 56;1–56.18
  69. Ploemacher RE, van Os R, van Beurden CA, Down JD. Murine hematopoietic stem cells with long-term engraftment and marrow repopulating ability are less radiosensitive to gamma radiation than are spleen colony forming cells. Int J Radiat Biol. 1992;61:489–499
  70. de Franceschi L, Turrini F, Honczarenko M, et al. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica. 2004;89:1287–1298
  71. Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells. Blood. 2003;101:4172–4179
  72. Ponka P, Grady RW, Wilczynska A, Schulman HM. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim Biophys Acta. 1984;802:477–489

PII: S0301-472X(08)00042-8

doi: 10.1016/j.exphem.2008.01.006

Experimental Hematology
Volume 36, Issue 7 , Pages 773-785 , July 2008

Article Tools

* Image Usage & Resolution